Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), ICAM-1 inhibitors(Intercellular adhesion molecule-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | US | 19 Apr 2023 | |
Melanoma | Preclinical | US | 19 Apr 2023 | |
Non-Small Cell Lung Cancer | Preclinical | US | 19 Apr 2023 |